Drug Development
After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.
FEATURED STORIES
Together with robust data-driven modeling, rethinking regulation and data use could push forward a notoriously challenging field.
From opening new therapeutic mechanisms to repairing neuronal damage, investigational molecules from Ventyx Therapeutics, AC Immune, Gain Therapeutics and more could shape the future of Parkinson’s disease treatment.
As drug candidates discovered via AI move into later-stage clinical trials, the technology seems to be doing as promised: speeding drug development.
Subscribe to ClinicaSpace
Clinical trial results, research news, the latest in cancer and cell and gene therapy, in your inbox every Monday
THE LATEST
The company said it would halt activities and focus its resources and time on liver and obesity research following “disappointing” results of its intranasal COVID-19 vaccine.
The COVID-19 pandemic has led to faster R&D, faster approvals, faster science than ever before. It’s even leading to faster company development.
Rinvoq shows promising results for Ulcerative Colitis Treatment. The company said more patients treated with Rinvoq in the 52-week study achieved clinical remission compared to placebo.
Here’s a look at some of the top COVID-19-related stories for today.
Orphazyme said that its OLE trial, which has been running for the past 24 months, showed that arimoclomol could be an effective and safe option in treating Niemann-Pick disease type C.
A new study published in Nature offers good news for those who recovered from COVID-19 and were then vaccinated with a mRNA vaccine – a booster may not be needed.
The groundbreaking success of the mRNA vaccines for COVID-19 by Pfizer-BioNTech and Moderna has led the way for other companies with a vested interest in vaccine development.
The two companies studying the regimen for HCC, Exelixis and Ipsen, suggest the probability of reaching significance at the final analysis is low.
Although the COVID-19 pandemic is waning in the U.S., it’s not completely over and there are some concerns, particularly with the delta variant, which originated in India. Here’s a look.
Polyphor said there has been no improvement in the results for FORTRESS, its Phase III global study for the possible treatment of patients with breast cancer.